Needham Maintains Buy on Arcutis Biotherapeutics, Raises Price Target to $40
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.
Needham analyst Serge Belanger maintains Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and raises the price target from $36 to $40.